Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

New Insights On Alzheimer's And What It Means For Personalized Medicine

New research studies reveal the complexity of AD, from classical Alzheimer's to mixed-type such as Alzheimer's with Lewy Bodies. Early detection of AD sub-types helps accelerate treatment innovations to unlock personalized medicine for Alzheimer's. In a joint study with the Oregon Health & Science University, Amprion conducted blinded analysis using CSF samples. During clinical test development, the SYNTap Test accurately predicted the presence of Lewy Bodies confirmed at later autopsy.


News provided by

Amprion

Jan 19, 2022, 06:00 ET

Share this article

Share toX

Share this article

Share toX

Amprion-New Insights on Alzheimer's
Amprion-New Insights on Alzheimer's

SAN FRANCISCO, Jan. 19, 2022 /PRNewswire-PRWeb/ -- A rapidly aging nation, the U.S. has 60 million people aged 65 and older. Of these, about 12 million people show early symptoms of Mild Cognitive Impairment. One in three of these people will progress to clinical Alzheimer's disease (AD) within five years.

New research studies reveal the complexity of AD, from classical Alzheimer's to mixed-type such as Alzheimer's with Lewy Bodies. Early detection of AD sub-types helps accelerate treatment innovations to unlock personalized medicine for Alzheimer's.

"for the first time, the SYNTap Test enables physicians to distinguish Alzheimer's with Lewy Bodies early—during patients' lifetimes. The advent of molecular diagnostics will accelerate innovations in personalized medicine for neurodegenerative diseases." CEO and Co-Founder Russ Lebovitz, M.D./Ph.D.

Post this

Traditionally, Alzheimer's has been characterized by the presence of two misfolded proteins: Abeta—producing plaques, and Tau—forming tangles.

Recent studies discovered a third misfolded protein, alpha-Synuclein (α-Synuclein), co-existing with Abeta and Tau, to form a new variant—Alzheimer's with Lewy Bodies. Research showed that up to 40% of deceased Alzheimer's patients had Lewy Bodies in their brains. The new finding was discovered through autopsy, the only method currently used to detect Lewy Bodies.

"This insight elevates our understanding of Alzheimer's as medical science strives to find cures for neurodegenerative diseases," said Claudio Soto, Ph.D., Amprion co-founder and chief scientific officer. Patients having AD with Lewy Bodies tend to progress faster than those with classical AD. In addition, these patients show overlapping symptoms of Lewy Body Dementia and Parkinson's disease. "Since AD with Lewy Bodies requires different treatments, it is critical to distinguish it early. Therefore, we're bringing to market the SYNTap™ Biomarker Test, which accurately detects misfolded α-Synuclein, to help differentiate this AD sub-type early," added Dr. Soto.

Awarded Breakthrough Device Designation by the U.S. FDA, Amprion SYNTap Test is performed in its top-of-the-class CLIA and CAP-accredited clinical laboratory in San Diego.

In a joint study with the Oregon Health & Science University, Amprion conducted blinded analysis using CSF samples. During clinical test development, the SYNTap Test accurately predicted the presence of Lewy Bodies confirmed at later autopsy. CSF samples were collected 1-15 years before autopsy from patients clinically diagnosed with AD (n=43), some other non-synucleinopathy neurodegenerative disease (n=12), and healthy control subjects (n=4).

Notably, the SYNTap Test detected the presence of misfolded α-Synuclein in CSF from a clinically diagnosed AD patient 10 years before the autopsy identified the presence of Lewy Bodies.

Similar results were observed in a confirmatory study performed with the University of California, San Diego using CSF collected before autopsy (n=64), as well as CSF collected postmortem (n=32). None of the CSF samples from 36 patients who had no brain Lewy Bodies at autopsy tested positive. During our clinical validation, the SYNTap Test detected the presence of misfolded α-Synuclein aggregates, the key component of Lewy Bodies, with sensitivity of 87.3% and a specificity of 97.2%.

Amprion Co-Founder and CEO Russ Lebovitz, M.D./Ph.D. expressed, "We are thrilled that for the first time in history, the SYNTap Test enables physicians to distinguish Alzheimer's with Lewy Bodies early—during patients' lifetimes. The advent of molecular diagnostics will accelerate innovations in therapeutics and personalized medicine for neurodegenerative diseases."

Team Amprion is looking forward to announcing more insightful research findings as we launch various clinical initiatives in the Alzheimer's, Parkinson's, and Lewy Body Dementia (or Dementia with Lewy Bodies) spaces.

Download the SYNTap Test specification sheet to learn more about its performance characteristics.

Gearing Up For More Breakthroughs In 2022
We look forward to making even more impactful discoveries in the New Year! Our top priorities include obtaining FDA approval for the SYNTap Test and expanding rollout into other countries. On the drug R&D front, Amprion is actively exploring strategic BioPharma partnerships to advance biomarker-targeted drugs and therapeutics for brain health.

ABOUT AMPRION
A leader in Prion Detection Science™, Amprion offers biomarker testing for brain diseases. The SYNTap™ Test helps physicians diagnose Parkinson's disease, Lewy Body Dementia, Alzheimer's with Lewy Bodies, and other neurological conditions. We plan to launch more biomarker tests to detect other brain disorders. Through molecular diagnostics, Amprion aims to accelerate biomarker-targeted drugs and therapeutics innovations. Personalized medicine for neurodegenerative diseases is our next frontier.

Media Contact

Jordan Lee, The PRGroup, 727-447-4992, [email protected]

SOURCE Amprion

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.